JP2013525438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525438A5 JP2013525438A5 JP2013508139A JP2013508139A JP2013525438A5 JP 2013525438 A5 JP2013525438 A5 JP 2013525438A5 JP 2013508139 A JP2013508139 A JP 2013508139A JP 2013508139 A JP2013508139 A JP 2013508139A JP 2013525438 A5 JP2013525438 A5 JP 2013525438A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- sulfonamide
- tetrahydroquinoline
- alkyl
- dimethylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 3,4-dihydroquinolin-2 (1H) -onyl Chemical group 0.000 claims 36
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XESJSVKSJFRHPE-UHFFFAOYSA-N 1-acetyl-n-(3,4-dimethylphenyl)-2,3-dihydroindole-5-sulfonamide Chemical compound C=1C=C2N(C(=O)C)CCC2=CC=1S(=O)(=O)NC1=CC=C(C)C(C)=C1 XESJSVKSJFRHPE-UHFFFAOYSA-N 0.000 claims 1
- KUMQIRFCKBSETE-UHFFFAOYSA-N 1-acetyl-n-(3,4-dimethylphenyl)-2-methyl-2,3-dihydroindole-5-sulfonamide Chemical compound C=1C=C2N(C(C)=O)C(C)CC2=CC=1S(=O)(=O)NC1=CC=C(C)C(C)=C1 KUMQIRFCKBSETE-UHFFFAOYSA-N 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- WVMOGAPSTDCYRO-UHFFFAOYSA-N 2-oxo-n-(3-phenylphenyl)-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 WVMOGAPSTDCYRO-UHFFFAOYSA-N 0.000 claims 1
- WQRPZEZBGHLTAC-UHFFFAOYSA-N 2-oxo-n-[3-(trifluoromethyl)phenyl]-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC(F)(F)C1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 WQRPZEZBGHLTAC-UHFFFAOYSA-N 0.000 claims 1
- DWLBYLGNERHAIR-UHFFFAOYSA-N 2-oxo-n-pyridin-3-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC1=CC=CN=C1 DWLBYLGNERHAIR-UHFFFAOYSA-N 0.000 claims 1
- ICWKDRRYYPUARX-UHFFFAOYSA-N 3,3-dichloro-n-(3,4-dimethylphenyl)-2-oxo-1h-indole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)C2(Cl)Cl)C2=C1 ICWKDRRYYPUARX-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- PNUCPERAJKCNDW-UHFFFAOYSA-N 6-(dimethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CN(C)C1=CC=2CCC(=O)NC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 PNUCPERAJKCNDW-UHFFFAOYSA-N 0.000 claims 1
- UKDWCJDLGFLUDX-UHFFFAOYSA-N 6-bromo-N-(3,4-dimethylphenyl)-3-oxo-4H-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Br)=CC2=C1NC(=O)CO2 UKDWCJDLGFLUDX-UHFFFAOYSA-N 0.000 claims 1
- NLCUMMKSKTZTBQ-UHFFFAOYSA-N 6-chloro-N-(3,4-dimethylphenyl)-3-oxo-4H-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(=O)CO2 NLCUMMKSKTZTBQ-UHFFFAOYSA-N 0.000 claims 1
- XRRWVAJHXHPVMF-UHFFFAOYSA-N 6-chloro-n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1NC(=O)C2 XRRWVAJHXHPVMF-UHFFFAOYSA-N 0.000 claims 1
- YGLBSBMBNJMIQH-UHFFFAOYSA-N 6-chloro-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 YGLBSBMBNJMIQH-UHFFFAOYSA-N 0.000 claims 1
- XRNQVMXHJDERIT-UHFFFAOYSA-N 6-chloro-n-(3-chloro-2-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CC1=C(Cl)C=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 XRNQVMXHJDERIT-UHFFFAOYSA-N 0.000 claims 1
- RFVFXQILUXVPQU-UHFFFAOYSA-N 6-chloro-n-(3-chloro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 RFVFXQILUXVPQU-UHFFFAOYSA-N 0.000 claims 1
- KEEWNCGXRMKJTQ-UHFFFAOYSA-N 6-chloro-n-(5-chloro-2-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-7-sulfonamide Chemical compound CC1=CC=C(Cl)C=C1NS(=O)(=O)C(C(=C1)Cl)=CC2=C1CCC(=O)N2 KEEWNCGXRMKJTQ-UHFFFAOYSA-N 0.000 claims 1
- CPCRMUCDKAAXGT-UHFFFAOYSA-N 7-(diethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CCN(CC)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CPCRMUCDKAAXGT-UHFFFAOYSA-N 0.000 claims 1
- JTMUYMFTDPYETO-UHFFFAOYSA-N 7-(dimethylamino)-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CN(C)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 JTMUYMFTDPYETO-UHFFFAOYSA-N 0.000 claims 1
- AOEUWFASGTXXAQ-UHFFFAOYSA-N 7-[2-(dimethylamino)ethyl-methylamino]-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CN(C)CCN(C)C1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 AOEUWFASGTXXAQ-UHFFFAOYSA-N 0.000 claims 1
- NFXGFWJXAFTFGK-UHFFFAOYSA-N 7-[3-(dimethylamino)pyrrolidin-1-yl]-n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1C(N(C)C)CCN1C(C(=C1)S(=O)(=O)NC=2C=C(C)C(C)=CC=2)=CC2=C1CCC(=O)N2 NFXGFWJXAFTFGK-UHFFFAOYSA-N 0.000 claims 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 1
- JPRSMOUDRVVIHR-UHFFFAOYSA-N N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound O1CCOC2=CC(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=C21 JPRSMOUDRVVIHR-UHFFFAOYSA-N 0.000 claims 1
- KQHKZXBKJWOHHU-UHFFFAOYSA-N N-(3-chlorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound ClC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 KQHKZXBKJWOHHU-UHFFFAOYSA-N 0.000 claims 1
- GTFOCOKDGPLBEK-UHFFFAOYSA-N N-(4-chloro-3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 GTFOCOKDGPLBEK-UHFFFAOYSA-N 0.000 claims 1
- BANOCBYMYBHZCK-UHFFFAOYSA-N N-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide Chemical compound C1=CC(F)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 BANOCBYMYBHZCK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- AIEOBFOLWRLWFY-UHFFFAOYSA-N [3-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)sulfonylamino]phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 AIEOBFOLWRLWFY-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- FXULHVBWXADQIT-UHFFFAOYSA-N n-(2-fluorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 FXULHVBWXADQIT-UHFFFAOYSA-N 0.000 claims 1
- HPTNHSMTBSTARS-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 HPTNHSMTBSTARS-UHFFFAOYSA-N 0.000 claims 1
- WDMSYXZEYIVUAV-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 WDMSYXZEYIVUAV-UHFFFAOYSA-N 0.000 claims 1
- TVEWYQNBFLBJON-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(Cl)C(Cl)=C1 TVEWYQNBFLBJON-UHFFFAOYSA-N 0.000 claims 1
- OZCHLLBJIJDZSV-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-1,3-dimethyl-2-oxobenzimidazole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(N(C)C(=O)N2C)C2=C1 OZCHLLBJIJDZSV-UHFFFAOYSA-N 0.000 claims 1
- PQRJAXXCZAABJD-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-1-methylindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(N(C)C=C2)C2=C1 PQRJAXXCZAABJD-UHFFFAOYSA-N 0.000 claims 1
- CKACPEDULOKSHJ-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3,4,5-tetrahydro-1-benzazepine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CCC2)C2=C1 CKACPEDULOKSHJ-UHFFFAOYSA-N 0.000 claims 1
- BSEGVWNGGVEPQX-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydrobenzimidazole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)N2)C2=C1 BSEGVWNGGVEPQX-UHFFFAOYSA-N 0.000 claims 1
- XMTTXQUJUKTALG-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)C2)C2=C1 XMTTXQUJUKTALG-UHFFFAOYSA-N 0.000 claims 1
- ABPIVUMUUZSCTQ-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-carboxamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=CC=C(NC(=O)CC2)C2=C1 ABPIVUMUUZSCTQ-UHFFFAOYSA-N 0.000 claims 1
- CAPFLYHFMYQPBI-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-(propan-2-ylamino)-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CC(C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CAPFLYHFMYQPBI-UHFFFAOYSA-N 0.000 claims 1
- PFQAFZFSUCEPGW-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-piperidin-1-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)N2CCCCC2)=CC2=C1NC(=O)CC2 PFQAFZFSUCEPGW-UHFFFAOYSA-N 0.000 claims 1
- ZMERFADMZRTONY-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-oxo-7-pyrrolidin-1-yl-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)N2CCCC2)=CC2=C1NC(=O)CC2 ZMERFADMZRTONY-UHFFFAOYSA-N 0.000 claims 1
- FLRPVXLMOJGRDV-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-3-oxo-4h-1,4-benzoxazine-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C1=CC=C(OCC(=O)N2)C2=C1 FLRPVXLMOJGRDV-UHFFFAOYSA-N 0.000 claims 1
- LFKHSAHGVHJEPF-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-3-oxo-6-phenyl-4h-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)C=2C=CC=CC=2)=CC2=C1NC(=O)CO2 LFKHSAHGVHJEPF-UHFFFAOYSA-N 0.000 claims 1
- CRZDZXNDKULTHH-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-4-methyl-3-oxo-1,4-benzoxazine-6-sulfonamide Chemical compound C1=C2N(C)C(=O)COC2=CC=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 CRZDZXNDKULTHH-UHFFFAOYSA-N 0.000 claims 1
- OHQSSKLYMQFLQN-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-6-methyl-3-oxo-4h-1,4-benzoxazine-7-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)C)=CC2=C1NC(=O)CO2 OHQSSKLYMQFLQN-UHFFFAOYSA-N 0.000 claims 1
- FTLNYBCPHCLODH-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(1-hydroxypropan-2-ylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OCC(C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-UHFFFAOYSA-N 0.000 claims 1
- WQEYRSZNQWSCKO-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(2-hydroxyethylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)NCCO)=CC2=C1NC(=O)CC2 WQEYRSZNQWSCKO-UHFFFAOYSA-N 0.000 claims 1
- RDJVVXIZIXTZEL-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-(methylamino)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CNC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 RDJVVXIZIXTZEL-UHFFFAOYSA-N 0.000 claims 1
- IAJXECZPLGLEKB-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-[(2-hydroxy-2-methylpropyl)amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)NCC(C)(C)O)=CC2=C1NC(=O)CC2 IAJXECZPLGLEKB-UHFFFAOYSA-N 0.000 claims 1
- FTLNYBCPHCLODH-CQSZACIVSA-N n-(3,4-dimethylphenyl)-7-[[(2r)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-CQSZACIVSA-N 0.000 claims 1
- FTLNYBCPHCLODH-AWEZNQCLSA-N n-(3,4-dimethylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(C)=C1 FTLNYBCPHCLODH-AWEZNQCLSA-N 0.000 claims 1
- MSHCFYZEHSRAPG-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(C)C(C)=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 MSHCFYZEHSRAPG-UHFFFAOYSA-N 0.000 claims 1
- QITDSYIYIPIMLL-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-n-methyl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)N(C)C1=CC=C(C)C(C)=C1 QITDSYIYIPIMLL-UHFFFAOYSA-N 0.000 claims 1
- HOPSYFZHYRZZBT-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound CC1=C(Cl)C=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 HOPSYFZHYRZZBT-UHFFFAOYSA-N 0.000 claims 1
- CUZDABRLLGGXKI-JTQLQIEISA-N n-(3-chloro-4-fluorophenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(F)C(Cl)=C1 CUZDABRLLGGXKI-JTQLQIEISA-N 0.000 claims 1
- NRHQXXODPRXAER-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 NRHQXXODPRXAER-UHFFFAOYSA-N 0.000 claims 1
- VLRYVDZPCCVRIS-LBPRGKRZSA-N n-(3-chloro-4-methylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(C)C(Cl)=C1 VLRYVDZPCCVRIS-LBPRGKRZSA-N 0.000 claims 1
- HYOLJEHGMOJMNR-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1NS(=O)(=O)C(C(=C1)F)=CC2=C1NC(=O)CC2 HYOLJEHGMOJMNR-UHFFFAOYSA-N 0.000 claims 1
- NQPXVAUSZJKKDP-UHFFFAOYSA-N n-(3-cyanophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NC1=CC=CC(C#N)=C1 NQPXVAUSZJKKDP-UHFFFAOYSA-N 0.000 claims 1
- YBQWWIYDCVJQAW-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(F)C(C)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 YBQWWIYDCVJQAW-UHFFFAOYSA-N 0.000 claims 1
- CBBKJQADPAHXLO-UHFFFAOYSA-N n-(3-fluorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 CBBKJQADPAHXLO-UHFFFAOYSA-N 0.000 claims 1
- IZMRNRGXIQXSKA-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 IZMRNRGXIQXSKA-UHFFFAOYSA-N 0.000 claims 1
- FGSXPFIJRVGTDM-UHFFFAOYSA-N n-(4-chloro-3-methylphenyl)-7-fluoro-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(Cl)C(C)=CC(NS(=O)(=O)C=2C(=CC=3NC(=O)CCC=3C=2)F)=C1 FGSXPFIJRVGTDM-UHFFFAOYSA-N 0.000 claims 1
- AISVTQYDRIQDKU-UHFFFAOYSA-N n-(4-chlorophenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC(Cl)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 AISVTQYDRIQDKU-UHFFFAOYSA-N 0.000 claims 1
- LPVLUUBCUWKBJT-UHFFFAOYSA-N n-(4-fluoro-3-methylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=C(F)C(C)=CC(NS(=O)(=O)C=2C=C3CCC(=O)NC3=CC=2)=C1 LPVLUUBCUWKBJT-UHFFFAOYSA-N 0.000 claims 1
- SLPTYIRATHEPAX-LBPRGKRZSA-N n-(4-fluoro-3-methylphenyl)-7-[[(2s)-1-hydroxypropan-2-yl]amino]-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound OC[C@H](C)NC1=CC=2NC(=O)CCC=2C=C1S(=O)(=O)NC1=CC=C(F)C(C)=C1 SLPTYIRATHEPAX-LBPRGKRZSA-N 0.000 claims 1
- AEYRWLQXGYDIOE-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)CC2)C2=C1 AEYRWLQXGYDIOE-UHFFFAOYSA-N 0.000 claims 1
- OCVBNKSYCFRIMO-UHFFFAOYSA-N n-benzyl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C=1C=C2NC(=O)CCC2=CC=1S(=O)(=O)NCC1=CC=CC=C1 OCVBNKSYCFRIMO-UHFFFAOYSA-N 0.000 claims 1
- OZKITVZVEHPSNT-UHFFFAOYSA-N n-naphthalen-1-yl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC=C2C(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=CC2=C1 OZKITVZVEHPSNT-UHFFFAOYSA-N 0.000 claims 1
- DVUSSGILUNAHHB-UHFFFAOYSA-N n-naphthalen-2-yl-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide Chemical compound C1=CC=CC2=CC(NS(=O)(=O)C=3C=C4CCC(NC4=CC=3)=O)=CC=C21 DVUSSGILUNAHHB-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32915810P | 2010-04-29 | 2010-04-29 | |
| US61/329,158 | 2010-04-29 | ||
| PCT/US2011/033852 WO2011137089A1 (en) | 2010-04-29 | 2011-04-26 | Activators of human pyruvate kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525438A JP2013525438A (ja) | 2013-06-20 |
| JP2013525438A5 true JP2013525438A5 (enExample) | 2014-04-10 |
Family
ID=44280778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508139A Pending JP2013525438A (ja) | 2010-04-29 | 2011-04-26 | ヒトピルビン酸キナーゼ活性剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130109672A1 (enExample) |
| EP (1) | EP2563761A1 (enExample) |
| JP (1) | JP2013525438A (enExample) |
| AU (1) | AU2011245441B2 (enExample) |
| CA (1) | CA2797694A1 (enExample) |
| WO (1) | WO2011137089A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
| WO2012088314A1 (en) * | 2010-12-21 | 2012-06-28 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| PT3406251T (pt) | 2011-05-03 | 2024-01-24 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| WO2012151440A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| WO2013027168A1 (en) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| NZ707778A (en) * | 2012-11-08 | 2019-03-29 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions and their use as pkm2 modulators |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CN105272904B (zh) * | 2014-07-18 | 2019-04-09 | 中国科学院广州生物医药与健康研究院 | N-苯基酰胺类化合物及其应用 |
| SG10201900631TA (en) | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
| FR3030518B1 (fr) | 2014-12-19 | 2018-03-23 | Galderma Research & Development | Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| FR3030516B1 (fr) | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| MX384883B (es) | 2015-06-11 | 2025-03-14 | Agios Pharmaceuticals Inc | Métodos para usar activadores de piruvato cinasa. |
| US10626087B2 (en) | 2015-07-10 | 2020-04-21 | Loyola University Of Chicago | Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| WO2019043208A1 (en) * | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN112105602A (zh) * | 2018-03-01 | 2020-12-18 | 反应生物公司 | 基于喹啉和异喹啉的hdac抑制剂及其使用方法 |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| SI4299135T1 (sl) | 2019-06-18 | 2025-12-31 | Pfizer Inc. | Benzizoksazolni sulfonamidni derivati |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| DE102019129527A1 (de) | 2019-10-31 | 2021-05-06 | Forschungszentrum Jülich GmbH | Inhibitoren für Bromodomänen |
| US20240000806A1 (en) * | 2020-11-20 | 2024-01-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for inhibiting cb1 activity |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE508815A (enExample) * | 1949-07-23 | |||
| US3998828A (en) | 1975-01-31 | 1976-12-21 | Pfizer Inc. | 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS569749A (en) * | 1979-07-04 | 1981-01-31 | Mitsubishi Paper Mills Ltd | Preparation of lithographic plate |
| DE2948434A1 (de) | 1979-12-01 | 1981-06-11 | Hoechst Ag, 6000 Frankfurt | 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4593102A (en) | 1984-04-10 | 1986-06-03 | A. H. Robins Company, Inc. | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| JPH0667926B2 (ja) | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| BR9200951A (pt) | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
| IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
| US5891435A (en) | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE69637380T2 (de) | 1995-01-20 | 2009-09-17 | G.D. Searle Llc, Chicago | Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen |
| JPH09286783A (ja) * | 1996-02-19 | 1997-11-04 | Fuji Photo Film Co Ltd | 感熱記録材料及びジアゾ化合物 |
| DE19629335A1 (de) | 1996-07-20 | 1998-01-22 | Golden Records Ass Internation | Karte aus Kunststoff |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| AR016551A1 (es) * | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
| AR016384A1 (es) | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| DE19755268A1 (de) * | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| PL351767A1 (en) | 1999-02-09 | 2003-06-16 | Dimensional Pharmaceuticals 3 | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors |
| US6211182B1 (en) | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
| CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| JP2003510278A (ja) | 1999-09-30 | 2003-03-18 | スミスクライン・ビーチャム・コーポレイション | カスパーゼおよびアポプトシス |
| JP2003535847A (ja) * | 2000-06-02 | 2003-12-02 | スージェン・インコーポレーテッド | 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体 |
| AR032885A1 (es) | 2000-08-16 | 2003-12-03 | Actelion Pharmaceuticals Ltd | Bis-sulfonamidas, composiciones farmaceuticas, procedimiento para prepararlas y el uso de las mismas para la produccion de las composiciones farmaceuticas |
| DE60228233D1 (de) | 2001-05-23 | 2008-09-25 | Max Planck Gesellschaft | Pyruvat-kinase als einem neuen zielmolekül |
| EP1492794B1 (en) | 2002-03-28 | 2007-12-12 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| ATE457025T1 (de) * | 2002-05-23 | 2010-02-15 | Cytopia Res Pty Ltd | Kinaseinhibitoren |
| AU2003237532B2 (en) | 2002-06-12 | 2009-07-30 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
| GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| WO2004076640A2 (en) | 2003-02-25 | 2004-09-10 | Ambion, Inc. | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same |
| JP2005008624A (ja) * | 2003-05-27 | 2005-01-13 | Taiho Yakuhin Kogyo Kk | テトラハイドロキノリン骨格を有するスルホンアミド誘導体およびその塩 |
| WO2005074946A1 (en) | 2004-02-10 | 2005-08-18 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
| WO2005080394A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| RU2261246C1 (ru) | 2004-04-15 | 2005-09-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Замещенные 7-сульфонил бензо[b][1,4]диазепины (варианты), способы их получения (варианты), фокусированная библиотека и фармацевтическая композиция |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| US8058313B2 (en) | 2004-06-24 | 2011-11-15 | Temple University—Of the Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| TW200606152A (en) | 2004-07-02 | 2006-02-16 | Tanabe Seiyaku Co | Piperidine compound and process for preparing the same |
| FR2872704B1 (fr) | 2004-07-12 | 2007-11-02 | Laurent Schwartz | Pluritherapie contre le cancer |
| WO2006055880A2 (en) | 2004-11-16 | 2006-05-26 | Genzyme Corporation | Diagnostic pkm2 methods and compositions |
| ES2430569T3 (es) | 2005-02-18 | 2013-11-21 | Astrazeneca Ab | Compuestos antibacterianos derivados de piperidina |
| EP1888558B1 (en) | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| AR054363A1 (es) | 2005-05-23 | 2007-06-20 | Astrazeneca Ab | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 |
| FR2887881B1 (fr) | 2005-07-01 | 2009-10-09 | Pierre Fabre Medicament Sa | Inhibiteurs de proteines kinases |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1965799A2 (en) | 2005-12-22 | 2008-09-10 | Merck & Co., Inc. | Substituted piperidines as calcium channel blockers |
| EP1962851A2 (en) | 2005-12-22 | 2008-09-03 | SmithKline Beecham Corporation | Compounds |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CN101404987A (zh) | 2006-01-20 | 2009-04-08 | 史密丝克莱恩比彻姆公司 | 磺酰胺衍生物在治疗代射和神经系统疾病中的用途 |
| US8987474B2 (en) * | 2006-04-07 | 2015-03-24 | University Of South Florida | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs |
| WO2007120638A2 (en) * | 2006-04-12 | 2007-10-25 | President And Fellows Of Harvard College | Methods and compositions for modulating glycosylation |
| DE602006014532D1 (de) | 2006-07-11 | 2010-07-08 | Sanofi Aventis | N-Ä(1,5-diphenyl-1H-pyrazol-3-yl)methylÜsulfonamid-Derivate Antagonisten der CB1 Rezeptoren der Cannabinoide |
| TW200817319A (en) * | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| CL2007003223A1 (es) | 2006-11-10 | 2008-01-11 | Wyeth Corp | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. |
| EP2132169A1 (en) | 2007-03-05 | 2009-12-16 | Biolipox AB | New methylenebisphenyl compounds useful in the treatment of inflammation |
| WO2008124838A1 (en) * | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
| WO2008130718A1 (en) | 2007-04-23 | 2008-10-30 | Atherogenics, Inc. | Sulfonamide containing compounds for treatment of inflammatory disorders |
| WO2009025781A1 (en) | 2007-08-16 | 2009-02-26 | Beth Israel Deaconess Medical Center | Activators of pyruvate kinase m2 and methods of treating disease |
| HUE025137T2 (en) * | 2007-08-21 | 2016-01-28 | Senomyx Inc | Compositions are bitter taste blocking (blocking) compounds |
| WO2009036341A2 (en) * | 2007-09-14 | 2009-03-19 | The Regents Of The University Of Michigan | Compositions and methods relating to hiv protease inhibition |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009084501A1 (ja) * | 2007-12-27 | 2009-07-09 | Asahi Kasei Pharma Corporation | スルタム誘導体 |
| GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| ES2620634T3 (es) | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| BR112012004149A2 (pt) | 2009-08-25 | 2016-03-22 | Abraxis Bioscience Llc | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog |
| WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
-
2011
- 2011-04-26 US US13/643,594 patent/US20130109672A1/en not_active Abandoned
- 2011-04-26 CA CA2797694A patent/CA2797694A1/en not_active Abandoned
- 2011-04-26 EP EP11730473A patent/EP2563761A1/en not_active Withdrawn
- 2011-04-26 AU AU2011245441A patent/AU2011245441B2/en not_active Expired - Fee Related
- 2011-04-26 WO PCT/US2011/033852 patent/WO2011137089A1/en not_active Ceased
- 2011-04-26 JP JP2013508139A patent/JP2013525438A/ja active Pending
-
2015
- 2015-03-10 US US14/643,107 patent/US9708267B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2797694A1 (en) | Activators of human pyruvate kinase | |
| JP2014525432A5 (enExample) | ||
| PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
| AR068423A1 (es) | Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| JP2017533968A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| JP2009536620A5 (enExample) | ||
| RU2015112192A (ru) | 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20080371A1 (es) | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 | |
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| JP2020502092A5 (enExample) | ||
| PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| AR077147A1 (es) | Compuestos biciclicos y triciclicos como inhibidores de kat ii | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| JP2011513410A5 (enExample) |